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We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients
with MBC were enrolled in a first-line combination therapy study with oral gefitinib (250mgday
 1) and intravenous docetaxel
(75mgm
 2, the first 14 patients; or 100mgm
 2, the following 27 patients, on day 1 of a 3-week cycle). Out of 41 patients, 38
received at least one cycle of therapy. There were no differences in activity or tolerability between the two docetaxel doses. G3/4
toxicities were neutropenia (49%), diarrhoea (10%), acne-like rash (5%), and anaemia (2%). Complete plus partial responses
(CRþPR) were observed in 22 out of 41 patients with a 54% response rate (95% confidence interval (CI) 45–75%). The 22 patients
that achieved a response following six cycles of docetaxel plus gefitinib continued gefitinib monotherapy (median duration, 24 weeks;
range, 2–108þ weeks). Two patients with PR following combination therapy achieved a CR during gefitinib monotherapy.
Complete plus partial responses correlated with oestrogen receptor (ER) status, since they occurred in 19 out of 27 (70%) patients
with ER-positive tumours as compared to three out of 14 (21%) patients with ER-negative tumours (P¼0.01).
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Breast cancer is the most common malignancy among women and
is the second leading cause of death for cancer in the Western
countries after lung cancer. Although only a minority of patients is
initially diagnosed with metastatic breast cancer (MBC), approxi-
mately 30–40% of all patients with early breast cancer, which are
treated with curative intent will ultimately develop metastatic
disease. Survival rates for MBC patients have been improved in
recent years. However, despite advances in therapy, MBC largely
remains an incurable disease and after documentation of
metastasis the median survival time is approximately 2 years
(Greenberg et al, 1996; Hortobagyi, 2002; Mincey and Perez, 2004).
Docetaxel is a first-generation taxane that has a wide spectrum of
antitumour activity and a number of unique characteristics
compared to other chemotherapeutic agents, including the other
taxane paclitaxel (Ringel and Horwitz, 1991; Riou et al, 1992;
Bissery et al, 1995; Montero et al, 2005). Docetaxel is active in MBC
patients (Nabholtz et al, 1999; Sjo ¨stro ¨m et al, 1999; Bonneterre
et al, 2002; O’Shaughnessy et al, 2002; Tabernero et al, 2004;
reviewed in Montero et al, 2005). In phase II studies docetaxel
treatment determines response rates (RR) of approximately 38–
68% (reviewed in Nabholtz and Gligorov, 2005). In phase III
studies, when it is used as single agent in previously untreated
women with MBC, docetaxel determines RR ranging between 30
and 48% (reviewed in Montero et al, 2005), whereas docetaxel in
combination with an anthracycline determines a RR of 42–59%
with a time to progression (TTP) ranging between 6.3 and 10.5
months (reviewed in Montero et al, 2005).
There is a large body of scientific evidence that the epidermal
growth factor receptor (EGFR) pathway contributes to a number of
processes involved in cancer cell proliferation, survival and
invasion rendering it an attractive target for anticancer therapy
(Ciardiello and Tortora, 2001). Studies in genetically modified
mice have suggested a role for the EGFR pathway in mammary
development and neoplastic transformation (Luetteke et al, 1999).
In fact, overexpression of the EGFR ligand, transforming growth
factor a (TGFa), in the mammary epithelium results in mammary
hyperplasias and carcinomas after a prolonged latency (Matsui
et al, 1990; Sandgren et al, 1990). Overexpression of EGFR is found
in 14–91% of breast cancer and this has been correlated with
disease progression and poor prognosis (Klijn et al, 1992; Fox et al,
1994; Klijn et al, 1994; Salomon et al, 1995).
There are several agents in clinical development that target the
EGFR, and two of the most effective pharmacologic approaches
currently under clinical investigation are small-molecule EGFR
tyrosine kinase inhibitors and EGFR-blocking monoclonal anti-
bodies (Ciardiello and Tortora, 2001; Grunwald and Hidalgo, 2003;
Mendelsohn and Baselga, 2003). Gefitinib (ZD1839, Iressat)i sa n
orally active, small-molecule, reversible EGFR tyrosine kinase
inhibitor (Herbst et al, 2004). Preclinical studies have shown that
gefitinib has a broad spectrum of antitumour activity including
human breast cancer (Ciardiello et al, 2000). Further, the
combination of gefitinib with different cytotoxic drugs including
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(Ciardiello et al, 2000; Sirotnak et al, 2000). In this respect, we
have demonstrated that gefitinib is active and restores the
sensitivity to docetaxel or to paclitaxel in multidrug-resistant,
taxane-resistant human breast cancer cells (Ciardiello et al, 2002).
Gefitinib is active also in breast cancer cell models which are
resistant to endocrine therapy (Nicholson et al, 2002; Knowlden
et al, 2003; Shou et al, 2004). In this respect, it has been shown that
the EGFR-dependent autocrine pathway plays a key role both in
intrinsic or de novo resistance to tamoxifen in ER positive, HER2
overexpressing MCF-7 breast cancer cells and in the acquired
resistance to tamoxifen in tamoxifen-treated MCF-7 cells (Nicholson
et al, 2002; Knowlden et al, 2003; Shou et al,2 0 0 4 ) .I nb o t h
experimental systems, gefitinib has a significant antitumour activity
(Nicholson et al, 2002; Knowlden et al, 2003; Shou et al, 2004).
Based on these preclinical data, we have performed a phase II
study of the combination of gefitinib and docetaxel as first-line
treatment in patient with MBC. We have evaluated the safety, the
tolerability profile and the clinical activity of gefitinib, 250mg
daily, in combination with docetaxel on a 3 weeks schedule at two
different doses (75mgm
 2 and 100mgm
 2).
PATIENTS AND METHODS
Patients
Female patients aged 18 years or older with histologically
confirmed MBC who had not previously received chemotherapy,
hormonal therapy, immunotherapy or treatment with monoclonal
antibodies for metastatic disease were eligible for this study.
Patients were required to have measurable disease as defined in the
Response Evaluation Criteria in Solid Tumours (RECIST) criteria
and adequate general health status (Eastern Cooperative Oncology
Group, ECOG, Performance Status, PS, 0–1). Patients who had
received prior radiotherapy within the 2 weeks before entry into
the trial were ineligible. Any patient with a history of a second
malignancy within 5 years, with the exception of curatively treated
basal cell carcinoma of the skin or cervical cancer in situ, was
ineligible. Absence of severe and uncontrolled systemic disease
such as unstable respiratory, cardiac, hepatic or renal disease was
required. The following laboratory parameters documented within
1 week before enrollment were required: absolute neutrophil count
(ANC) greater than 1.5 10
9l
 1 (L) and platelets greater than
100 10
9l
 1; ALT or ASTp1.5 times the upper limit of normal
range (ULRR) and alkaline phosphatase of p2.5 times the ULRR;
bilirurbin within normal limits and creatinine of p1.5 times the
ULRR. Women of childbearing potential should have had a
negative pregnancy test before enrollment and were advised to
practice appropriate contraception while on study. Patients were
excluded from treatment with phenytoin, carbamazepine, barbi-
turates or rifampicin while on protocol. Concomitant bispho-
sphonates were allowed for patients with bone metastasis. This
study was conducted in accordance with the Declaration of
Helsinki and the study protocol was reviewed and approved by the
local Research Ethics Committees (University of Naples and
Ospedale SG Moscati, Avellino). Before study entry, each patient
signed a written informed consent. Patients were enrolled between
August 2002 and May 2004. Data analysis has been performed 12
months after the last patient had been enrolled (31 May 2005). The
median follow-up was 23 months (range, 12–34 months).
Treatment plan
Docetaxel and gefitinib combined treatment was planned for initial
three cycles. Patients who had a clinical response (i.e. patients with
complete response (CR), partial response (PR), or stable disease
(SD)) after the first three clycles received additional three cycles of
combination therapy. Gefitinib was continued as monotherapy
only for patients who had CR or PR after the end of six cycle of
combination therapy and this treatment was given until disease
progression, unacceptable toxicity or withdrawal of consent.
Patients received gefitinib, 250mg, orally, once daily, continuously,
in the morning at approximately the same time each day. The
initial docetaxel dose was 75mgm
 2 as intravenous (i.v.) admin-
istration for 60min, every 3 weeks. Docetaxel dose was escalated to
100mgm
 2 i.v. administration for 60min, every 3 weeks, after the
first 14 patients completed the planned treatment without the
occurrence of any unacceptable toxicity as defined by an event that
required dosage reduction or interruption in more than three
patients. Patients received three doses of prophylactic dexametha-
sone, 8mg i.m., every 12h starting the 24h before docetaxel
infusion. Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC), Version 2.0. Dose
interruption was planned for NCI-CTC grade 3 and 4 toxicity
related to gefitinib. Once the toxicity decreased in severity to grade
1, the patient may have continued on the assigned dose. Repeated
dose interruptions were allowed as required, for a maximum of 14
days on each occasion. No dose reduction was allowed. If toxicity
recurred after drug rechallenge, and further interruptions were
considered insufficient to manage the toxicity, gefitinib disconti-
nuation was required and patients were withdrawn from the trial.
To manage docetaxel-related toxicity, treatment with docetaxel was
delayed by no more than 2 weeks. If treatment was delayed for
either haematologic or nonhaematologic toxicity for more than 2
weeks, the patients were withdrawn from the trial. In case of grade
2 neutropenia and of grade 3 thrombocytopenia, treatment with
docetaxel was delayed until toxicity was resolved to grade 1 or less.
In case of repeated delays due to grade 2 neutropenia, the dose of
docetaxel could be reduced to 75mgm
 2 or to 50mgm
 2, for all
the subsequent infusions in patients who received, respectively, the
initial docetaxel dose of 100mgm
 2 or of 75mgm
 2. If further
delays were required the patients would have been withdrawn from
the trial. The treatment with docetaxel was planned to be
discontinued with patients taken off study in case of grade 4
neutropenia for 7 days or more and/or grade 3–4 neutropenia with
axilar fever X381C or documented infection.
Patient clinical evaluation and assessment of response
Before study entry, a complete medical history, physical examina-
tion including performance status, height, weight and vital signs,
electrocardiogram, urine analysis, pregnancy test if indicated, and
radiographic tumour assessment within 21 days before start
treatment were performed. Patients were evaluated at the start of
each cycle during the combination treatment with physical
examination, laboratory tests while adverse reactions were docu-
mented every week, whereas radiographic tumour assessment was
repeated at the end of cycles 3 and 6. During gefitinib monotherapy,
physical examination, haematology, biochemistry, evaluation of
adverse events and radiographic tumour assessment were per-
formed every 6 weeks until patient progression or trial closure.
Study end points
The primary objective of this trial was to evaluate the activity of
oral gefitinib administration in combination with docetaxel as
first-line treatment in patients with MBC by estimating the
objective tumour response rates (CR and PR) according to the
RECIST criteria (Therasse et al, 2000). Secondary objectives were
to estimate the disease control rate (CR, PR plus SD), the TTP, the
overall survival (OAS) and to further characterise the safety and
tolerability profile of gefitinib, 250mg daily dose, alone and in
combination with every 3 weeks i.v. docetaxel. Responses were
evaluated by the investigators and were confirmed after 4 weeks.
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This was an open, noncomparative, two centre, phase II trial. The
Fleming’s method was used to calculate the number of patients
required (Fleming, 1982). A sample size of 41 patients was
calculated as sufficient to give an 80% probability of rejecting a
baseline RR of 35% with an exact 5% one-sided significance test
when the true response is at the clinically relevant rate of 55%. The
hypothesis that the RR is equal or less than the baseline was
considered to be rejected if 20 or more responses were observed in
the 41 patients. All patients that were enrolled and received trial
treatment were considered as the intention-to-treat (ITT) popula-
tion. The analysis population for all efficacy end points were the
ITT population. Response rates were estimated using the exact
two-sided type 95% confidence interval (CI) method based on the
binomial proportions. The association between the different
clinicopathologic characteristics and responses to treatment was
studied by the use of contingency tables. Statistical significance
was evaluated by the Pearson w
2 test. Duration of response, TTP
and OAS were estimated by the Kaplan–Meier method (Kaplan
and Meier, 1958).
RESULTS
Patients characteristics
A total of 41 female patients with MBC, who had not previously
received chemotherapy or hornomotherapy for metastatic disease,
were enrolled in this study. The clinical characteristics of these
women are listed in Table 1. The median age was 58 years; most
women had a good ECOG PS, in particular 39 patients (95%) had a
PS 0 at screening, while only two patients had a PS 1 (5%). The
prevalent histotype was ductal infiltrating carcinoma (37 out of 41
patients, 90%), while four patients (10%) had a lobular infiltrating
carcinoma. The majority of women (83%) had visceral disease.
Five of the patients on study (12%) had HER-2 3þ at the
immunohistochemistry screening of the primary tumour, 22 (54%)
patients had a HER-2-negative tumour, whereas the HER-2 status
of 14 (34%) patients was not known. Tumours in 27 patients were
oestrogen receptor-positive (66%) and in 14 cases (34%) were ER
negative. Most patients had received, in the adjuvant setting, prior
chemotherapy and hormonotherapy (tamoxifen, 20mg daily
planned for 5 years) (73 and 59%, respectively). The 24 patients
that had received adjuvant hormonotherapy therapy were treated
with tamoxifen for 6 months to 5 years (median, 3 years). Of the
patients, 22 (54%) had been treated with antracyclines and six
patients (15%) had received a taxane in the adjuvant setting.
Toxicity
A total of 216 cycles (median, 5.2. cycles; range, 1–6) of docetaxel
infusions were administrated. None of the patients had docetaxel
dose delay and no woman developed toxicity requiring dose
adjustment of docetaxel. The first 14 patients were treated for up to
six cycles with the combination of docetaxel (75mgm
 2 dose) and
gefitinib. Since no major toxicity occurred, as per protocol
planning, the following 27 patients enrolled in this study were
treated with combination of docetaxel (100mgm
 2 dose) and
gefitinib. There were no differences in grade and profile of toxicity
between the two docetaxel doses. Therefore, toxicity data are
presented on the whole 41 patient population. Thirty eight patients
received at least one cycle of combination therapy with docetaxel
and gefitinib. In general, treatment was well tolerated. The worst
grades of treatment-related toxicity for the 41 patients are listed in
Table 2. Three patients developed, despite the required premedica-
tion with dexamethasone, hypersensitivity reactions after a few
minutes of starting the first i.v. infusion of docetaxel. These
women, who were never treated with gefitinib, were taken off
protocol and switched to a chemotherapy regimen without
docetaxel. Haematologic toxicity was noted in the majority of
patients during the combination treatment period with grade 3 or
4 neutropenia affecting 49% of patients. Neutropenia was the only
grade 4 haematologic toxicity observed. No patients developed
neutropenic fever. Grade 3 anaemia occurred in one patient. There
was minimal thrombocytopenia. Nonhaematologic toxicities re-
lated to study treatment are also listed in Table 2. Gastrointestinal
side effects such as nausea/vomiting or stomatitis were mild with
only grade 1 or 2 toxicity recorded. Grade 3 diarrhoea occurred in
four patients (10%) and was controlled with loperamide admin-
istration. Only one patient with grade 3 diarrhoea refused further
treatment after one cycle of combination therapy. Neuropathy
affected 17% of patients and none exceeded grade 2 toxicity.
Several patients developed asthenia, but only two with grade 3
toxicity. Abnormal values for ALT and/or AST were reported in 11
patients, but only in two patients reached grade 3 toxicity. Two
patients had grade 3 acne-like rash after the first cycle of
combination therapy. After 1 week of gefitinib treatment suspen-
sion and recover to grade 1 skin toxicity, treatment with gefitinib
was restarted. In these two patients, the intensity of this skin
reaction did not exceed grade 2 with the following cycles of
combination treatment. However, two of the three patients who
experienced grade 2 skin toxicity decided to withdraw their
consent after one cycle of combination therapy and were switched
to a different chemotherapy regimen.
Table 1 Patient characteristics
Patients (N¼41)
N %
Age (years)
Median 58
Range 40–75
ECOG performance status
03 9 9 5
12 5
20 0
Histology
Ductal infiltrating carcinoma 37 90
Lobular infiltrating carcinoma 4 10
ER expression (IHC)
Positive 27 66
Negative 14 34
HER-2 expression (IHC)
3+ 5 12
Negative 22 54
Unknown 14 34
Prior adjuvant therapy
Yes 30 73
No 11 27
Prior adjuvant chemotherapy 30 73
Prior adjuvant anthracyclines 22 54
Prior adjuvant taxanes 6 15
Prior adjuvant hormonotherapy (tamoxifen) 24 59
Dominant sites of disease
Visceral 34 83
Soft tissue (lymph nodes and bone sites)
a 71 7
aNo patient had only bone metastases.
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Of 41 patients enrolled in this study, three were never treated with
gefitinib, because they had to stop the first adminstration of i.v.
docetaxel on day 1 of the first cycle without receiving gefitinib due
to hypersensitivity reactions to docetaxel. On an intention to treat
analysis of the entire 41 patient population, major clinical
responses were observed in 22 patients for an overall RR of 54%
(CI, 45–75%) (Table 3). Five CR and 17 PR were observed. Two of
the 17 patients with PR following completing the six cycles of
docetaxel–gefitinib combination therapy achieved a CR during
gefitinib monotherapy. Six patients (14%) had a SD and 13 patients
(32%) experienced disease progression. The 22 patients that
achieved a response following six cycles of docetaxel plus gefitinib
continued gefitinib monotherapy (median duration, 24 weeks;
range, 2–108þ weeks). Major responses (CRþPR) were evalu-
ated in correlation with all clinical and pathologic characteristics
(listed in Table 1) of the patients. No significant correlation was
observed between the achievement of a clinical response and any
parameter which was evaluated, except for a statistically significant
association between response to treatment and ER status (Table 4).
In fact, in those patients with ER-positive tumours, CRþRP were
observed in 19 out of 27 (70%) patients, whereas among patients
with ER-negative cancers the RR was three out of 14 (21%)
patients. If we consider only the 35 patients who were treated with
gefitinib and docetaxel combination for at least two cycles of
therapy, major clinical responses (CRþRP) were observed in 19
out of 23 (82%) patients with ER-positive tumours, whereas among
patients with ER-negative cancers the RR was three out of 12
(25%). The median OAS in the entire population of 41 patients
enrolled in this study could not be calculated at the time of the
analysis for the low numbers of deaths occurred. The median TTP
which was analysed on an intention to treat basis on the all 41
patients was 8.2 months. The median duration of response for
responding patients was 6.5 months (range, 3–23.5þ months).
DISCUSSION
To our knowledge this is the first report on docetaxel and gefitinib
combination as first-line treatment of patients with MBC. The
results of this study suggest that treatment with docetaxel and
gefitinib is an active and generally well-tolerated regimen in
women with MBC who have not been previously treated for
metastatic disease. Most of the toxicities observed were consistent
with those expected when using docetaxel as single agent (reviewed
in Montero et al, 2005). The most frequent G3/4 toxicity was
neutropenia, although no febrile neutropenia or neutropenic
infection occurred. Peripheral neuropathy and asthenia observed
in this trial were also similar to those observed with single agent
docetaxel given every 3 weeks (reviewed in Montero et al, 2005).
The adverse events associated with gefitinib were diarrhoea and
acne-like rash and were in line with the reported safety profile for
this drug (Herbst et al, 2004). In particular, two patients
experienced grade 3 skin toxicity. However, after 1 week of
treatment suspension, gefitinib was restarted and the intensity of
this skin reaction did not exceed grade 2 thereafter.
The RR reported in this trial are in a range which is comparable
to those obtained when docetaxel is combined with antracyclines
(reviewed in Montero et al, 2005). Several studies have been
published on the combination of docetaxel with trastuzumab, the
first therapeutic agent targeting the human epidermal growth
factor receptor-2 (HER2) which has been used in breast cancer
(Baselga et al, 1996). Trastuzumab is currently used in association
Table 2 Worst grade of toxicity for the 41 patients
Grade
1234
Toxicity Patients % Patients % Patients % Patients %
Anaemia 7 17 4 10 1 2 0
Thrombocytopenia 2 5 0 0 0
Neutropenia 12 29 4 10 6 15 14 34
Nausea 8 20 4 10 0 0
Vomiting 5 12 2 5 0 0
Stomatitis 2 5 2 5 0 0
Diarrhoea 9 22 5 12 4 10 0
Mucositis 7 17 2 5 0 0
Pain 1 2 0 0 0
Fever 2 5 5 12 0 0
Hypersensitivity
a 00 3 7 0
Neuropathy 6 15 1 2 0 0
Acne-like rash 4 10 3 7 2 5 0
Asthenia 6 15 4 10 2 5 0
Increase in transaminases 6 15 3 7 2 5 0
aHypersensitivity reactions after few minutes of starting the first intravenous injection of docetaxel were observed in three patients, which, therefore, were never treated with
gefitinib and which were switched to a chemotherapy regimen without docetaxel. Toxicities were recorded according to the National Cancer Institute Common Toxicity Criteria
(NCI-CTC) version 2.0.
Table 3 Response to therapy for the 41 patients
Patients (N¼41)
Response N %
Overall response 22 54
Complete response (CR) 5 12
Partial response (PR) 17 42
Stable disease (SD) 6 14
Progressive disease (PD) 13 32
Among these 41 patients, three were never treated with gefitinib, because they had
to stop the first adminstration of i.v. docetaxel on day 1 of the first cycle before
receiving gefitinib due to hypersensitivity reactions to docetaxel. Three additional
patients refused further therapy after one cycle. Refusal was due to grade 3 diarrhoea
in one patient and to grade 2 acne-like rash in the other two patients. For the
intention to treat analysis, all six patients were recorded as patients with progressive
disease.
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women who have been selected for having HER2 overexpressing
MBC. In particular, several phase II studies of trastuzumab in
combination with docetaxel, as first- or as second-line treatment
for patients with HER2 – overexpressing MBC, have been reported
with RR ranging from 45 to 72% (Burris, 2001; Esteva et al, 2002;
Montemurro et al, 2004; Tedesco et al, 2004). More recently,
the results of a randomised phase II trial evaluating the activity
and the efficacy of trastuzumab plus docetaxel in the first-line
treatment of HER2 – overexpressing MBC patients have
been reported (Marty et al, 2005). In this study, a 61% RR, a
11.7 months TTP and a 31.2 months median OAS have been
observed.
A potentially interesting observation which emerges from our
study is that a statistically significant association has been found
between clinical response to gefitinib plus docetaxel treatment and
ER status (Table 4). In fact, in those patients with ER-positive
tumours, the RR is 70%, whereas among patients with ER-negative
cancers the RR is 21%. The majority of patients who experienced
SD or PD had ER-negative tumours. These clinical data may be
explained by the recent experimental findings in MCF-7 human
breast cancer cells, which are initially oestrogen-dependent for
growth and sensitive to the antioestrogen tamoxifen. MCF-7 cells
which are chronically cultured in the presence of tamoxifen
generally become tamoxifen-resistant between 3 and 6 months
(Nicholson et al, 2002; Knowlden et al, 2003). Tamoxifen-resistant
MCF-7 cells exhibit markedly increased levels of EGFR and HER-2
as compared to tamoxifen-sensitive parental MCF-7 cells (Nicholson
et al, 2002; Knowlden et al, 2003). Furthermore, these cells exhibit
an increased dependence on EGFR signaling for proliferation and
survival and they become extremely sensitive to gefitinib
(Nicholson et al, 2002). Therefore, a possible interpretation for
the findings of our study is that women with ER-positive-tumours,
which have been treated chronically up to 5 years in the adjuvant
setting with the antioestrogen tamoxifen, may have eventually
developed a MBC in which the EGFR-driven pathway has become
important for cancer cell growth and for such reason become
sensitive to gefitinib. In this context, the EGFR signaling pathway
which is upregulated in tamoxifen-resistant ER-positive breast
cancer would be of critical relevance in the escape from the growth
inhibition induced by the antioestrogen tamoxifen. The possibility
that women with ER-positive breast cancer may be selected for the
treatment with EGFR inhibitors is supported also by the
preliminary results of a phase II study in which it has been
investigated the activity and safety of gefitinib in patients with
tamoxifen-resistant ER-positive breast cancer (Robertson et al,
2003). In this trial, 66% of patients with tamoxifen-refractory
disease achieved a clinical benefit (PR plus SD) with gefitinib
monotherapy, as compared to only 11% of patients with ER-
negative disease. On the contrary, three phase II studies in
unselected, heavily pretreated women with MBC have shown that
gefitinib monotherapy has minimal clinical activity with RR
ranging between 0 and 2% (Albain et al, 2002; Baselga et al,
2005; von Minckwitz et al, 2005). However, a randomised phase II
trial has recently shown that a short 4- to 6-weeks treatment with
gefitinib monotherapy or with gefitinib plus the aromatase
inhibitor anastrozole in postmenopausal breast cancer patients
with ER-positive and EGFR-positive tumours before curative
surgery determines PR in 12 out of 22 patients and in 14 out of
28 patients, respectively (Polychronis et al, 2005). These findings
suggest a direct antiproliferative effect of gefitinib in this untreated
breast cancer patient population.
In summary, the results of this study suggest that treatment with
gefitinib in combination with docetaxel is a potentially active and
well-tolerated regimen in untreated patient with MBC. A clinically
relevant issue is the identification of potential predictive factors,
which could help to select breast cancer patients who could
respond to anti-EGFR targeted therapies. The results of this study
suggest that women with ER-positive tumours have a higher RR
and are most likely the patients that could benefit from the
docetaxel plus gefitinib combination. However, further clinical
translational research studies are necessary to define the role of
gefitinib alone and/or in combination with docetaxel in the
management of this subset of MBC patients.
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